{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:30:14Z","timestamp":1753893014905,"version":"3.41.2"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>While many countries have successfully promoted generic drug use, South Korea faces challenges with low utilization and high expenditure shares, despite various policy reforms. This study aimed to evaluate the effectiveness of generic drug policies in South Korea, by comparing the prices, competition, and usage trends of generic drugs between South Korea and the Group of Twenty (G20) countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed 26 off-patent active ingredients marketed in South Korea and G20 countries from 2014 to 2023. Generic drug prices were calculated by dividing total sales by total volume in 2023, with the average price for each country subsequently determined. Generic competition was measured by the number of generic drugs available in each country. The usage trends of generic drugs were assessed using the sales and volume ratios of off-patent original drugs to generic drugs in 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>South Korea had more generic drugs for 19 of the 26 analyzed ingredients (73.1%) compared to other G20 countries. However, for recently off-patent ingredients, the number of generic drugs was smaller in South Korea. The generic prices for 18 ingredients (69.2%) were lower in South Korea than in the G20 and Advanced Eight (A8) countries. Similar to the generic competition, generics with larger market sizes had higher prices in South Korea. Conversely, the prices of recently off-patent ingredients were higher in South Korea compared to the G20 countries. For 24 ingredients (92.3%), the sales and volume ratios of generic drugs in South Korea were considerably lower compared to the G20 countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study confirms that the pharmaceutical policies and regulatory frameworks for generic drug are fragmented and inefficient in South Korea. Consequently, these fragmented and inefficient policies disrupt the virtuous cycle mechanism of generic price and usage driven by effective competition. To address these challenges and promote the use of generic drugs, the findings of this study suggest the need to develop and implement policies in South Korea that focus on optimizing the pharmaceutical expenditure structure, enhancing post-listing price management system for generic drugs, supporting the accelerated development of generic drugs, and promoting the prescription and use of generic drugs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1559823","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T13:57:06Z","timestamp":1748354226000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["International comparison of generic competition, prices, and usage trends: South Korea and G20 countries"],"prefix":"10.3389","volume":"13","author":[{"given":"Da Hye","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Ae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Min","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Won","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon-A","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Hyuk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.healthpol.2014.06.004","article-title":"Interventions promoting the acceptance and uptake of generic medicines: a narrative review of the literature","volume":"117","author":"Babar","year":"2014","journal-title":"Health Policy."},{"volume-title":"How to Increase Patient Access to Generic Medicines in European Healthcare Systems","year":"2009","author":"Bongers","key":"B2"},{"key":"B3","first-page":"1","article-title":"The rise and impact of generic drugs in modern healthcare","volume":"11","author":"Hussain","year":"2023","journal-title":"Int Res J Pharm Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"151939","DOI":"10.1016\/j.semarthrit.2021.11.009","article-title":"The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems","volume":"52","author":"Kvien","year":"2022","journal-title":"Semin Arthritis Rheum."},{"key":"B5","unstructured":"The Role of Generic Medicines in Sustaining Healthcare Systems: A European Perspective\n          \n          2015"},{"key":"B6","doi-asserted-by":"publisher","first-page":"934161","DOI":"10.3389\/fpubh.2022.934161","article-title":"Who initiates price competition when generic entrants are introduced into the South Korean pharmaceutical market?","volume":"10","author":"Son","year":"2022","journal-title":"Front Public Health."},{"volume-title":"Analyze and Manage Drug Spend Factors","year":"2018","author":"Park","key":"B7"},{"key":"B8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/1741134311422466","article-title":"Addressing escalating health care costs in ageing populations by increasing generic medicine utilization","volume":"8","author":"Simoens","year":"2011","journal-title":"J Generic Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2050-6511-14-1","article-title":"A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study","volume":"14","author":"Dunne","year":"2013","journal-title":"BMC Pharmacol Toxicol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1097\/MJT.0000000000000282","article-title":"Potential clinical and economic impact of switching branded medications to generics","volume":"24","author":"Straka","year":"2017","journal-title":"Am J Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jsps.2013.12.017","article-title":"The experiences of implementing generic medicine policy in eight countries: a review and recommendations for a successful promotion of generic medicine use","volume":"22","author":"Hassali","year":"2014","journal-title":"Saudi Pharm J."},{"key":"B12","first-page":"103","article-title":"The volume and the price of generic drug consumption in Korea prescription drug market","volume":"14","author":"Shin","year":"2008","journal-title":"Health Econ Policy Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40258-014-0145-2","article-title":"A systematic review of physicians' and pharmacists' perspectives on generic drug use: what are the global challenges?","volume":"13","author":"Toverud","year":"2015","journal-title":"Appl Health Econ Health Policy."},{"key":"B14","first-page":"462","article-title":"Encouraging the use of generic medicines: implications for transition economies","volume":"43","author":"King","year":"2002","journal-title":"Croat Med J."},{"key":"B15","first-page":"23","article-title":"Trend in the market share of generic drugs after the first generic entry","volume":"23","author":"Yang","year":"2017","journal-title":"Korean Health Econ Policy Assoc."},{"volume-title":"Current Status and Implications of Foreign Generics Enablement Policies","year":"2019","author":"Choi","key":"B16"},{"volume-title":"Review and Implications of Generic Drug Promotion Policies in Major Countries","year":"2014","author":"Kim","key":"B17"},{"key":"B18","unstructured":"Europe\n              MF\n            \n          \n          Market Review \u2013 European Generic Medicine Markets\n          \n          2023"},{"volume-title":"Study on Insurance Drug Price Adjustment Plan.","year":"2010","author":"Bae","key":"B19"},{"volume-title":"Health Insurance Drug Expenditure Efficiency Plan","year":"2020","author":"Park","key":"B20"},{"volume-title":"Trends in Generic Drug Pricing Systems in Major Countries for Drug Cost Follow-Up","year":"2019","author":"Byun","key":"B21"},{"key":"B22","first-page":"13","article-title":"Policy on promoting the use of generic medicines abroad","volume":"2","author":"Kim","year":"2007","journal-title":"Int Soc Secur Trends"},{"volume-title":"Recent Developments in the UK's Drug Prescribing Incentives","year":"2020","author":"Lee","key":"B23"},{"volume-title":"Effectiveness Analysis and Model Improvement of Prescription Drug Cost Reduction Incentive Program","year":"2018","author":"Kim","key":"B24"},{"volume-title":"Considering Policies to Encourage the Use of International Low-cost Drugs","year":"2017","author":"Lee","key":"B25"},{"volume-title":"Drug Expendture Dynamics 1995\u20132020: Understanding Medicine Spending in Context","year":"2021","key":"B26"},{"key":"B27","unstructured":"Kwon\n              SM\n            \n            \n              Heo\n              JH\n            \n            \n              Kim\n              SJ\n            \n            \n              Park\n              JE\n            \n          \n          Study on Efficient Drug Postpayment Management System\n          \n          2013"},{"key":"B28","first-page":"529","article-title":"Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry","volume":"35","author":"Suh","year":"2000","journal-title":"Health Serv Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/1468-0009.12517","article-title":"The evolution of supply and demand in markets for generic drugs","volume":"99","author":"Frank","year":"2021","journal-title":"Milbank Q."},{"key":"B30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40258-018-0406-6","article-title":"The impact of patent expiry on drug prices: a systematic literature review","volume":"16","author":"Vondeling","year":"2018","journal-title":"Appl Health Econ Health Policy."},{"key":"B31","unstructured":"Welfare\n              MoHa\n            \n          \n          The Health and Welfare White Paper\n          \n          2022"},{"key":"B32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s43441-025-00741-x","article-title":"A five-year analysis of market share and sales growth for original drugs after patent expiration in Korea","volume":"59","author":"Bae","year":"2025","journal-title":"Ther Innov Regul Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/healthcare8030233","article-title":"Price-cutting trends in new drugs after listing in South Korea: the effect of the reimbursement review pathway on price reduction","volume":"8","author":"Kim","year":"2020","journal-title":"Healthcare"},{"key":"B34","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40258-017-0307-0","article-title":"Drug pricing in South Korea","volume":"15","author":"Kwon","year":"2017","journal-title":"Appl Health Econ Health Policy."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1307462","DOI":"10.3389\/fphar.2023.1307462","article-title":"Price increase negotiations to address drug shortages in South Korea's national health insurance","volume":"14","author":"Yu","year":"2023","journal-title":"Front Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/cts.13161","article-title":"Analysis of the Korean generic medicine market: factors affecting the market share of generic medicines","volume":"15","author":"Kim","year":"2022","journal-title":"Clin Transl Sci."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1559823\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T13:57:15Z","timestamp":1748354235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1559823\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":36,"alternative-id":["10.3389\/fpubh.2025.1559823"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1559823","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"article-number":"1559823"}}